Brought to you by 
Neuro start-up Envoy brings in $8mm through Series A financing
29 Oct 2009
Executive Summary
Start-up CNS drug developer Envoy Therapeutics has grossed $8mm through the sale of Series A preferred shares to lead backer 5AM Ventures and other investors including Takeda Research Investment and Roche Venture Fund.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neuro start-up Envoy brings in $8mm through Series A financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice